drugset / Trial / NCT00031837

Gemcitabine With or Without Dalteparin in Treating Patients With Unresectable or Metastatic Pancreatic Cancer

NCT00031837

Phase 3 Terminated 400 enrolled Gary Morrow National Cancer Institute (NCI) · collab
RandomizedParallel-groupOpen-labelTreatment

Summary

RATIONALE: Drugs used in chemotherapy, such as gemcitabine, work in different ways to stop tumor cells from dividing so they stop growing or die. Anticoagulants such as dalteparin may help prevent blood clots in patients being treated with gemcitabine for unresectable or metastatic pancreatic cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of gemcitabine with or without dalteparin in treating patients who have unresectable or metastatic pancreatic cancer.

Timeline

Start
2002-10
Primary completion
2006-12
Completion
2006-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Dalteparin sodium Other / unclassified 5000 iu Subcutaneous
Background Gemcitabine Small molecule 1000 mg/m2 Intravenous